Sonic Healthcare: The Future Looks Bright
Scott Power
Morgans
Sonic FY15 results were in-line with our expectations, with solid top-line growth constrained by well-flagged challenging market conditions in both Australia and US pathology flat-lining underlying profit. However, we believe the worst is behind us, as strengthening 2H organic volume growth across all regions, a restructured US business, along with ongoing cost-out initiatives, uplift from recent acquisitions and FX tailwinds, strengthen our confidence in a solid recovery and return to a more stable earnings growth profile. (SHL, Add, Price Target A$22.33) Report attached, here is the link to the blog site (VIEW LINK)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
1 topic
1 stock mentioned
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment